Allergan signs $3.34bn neurology deal with Heptares; partnership terminated
On the heels of its recent break-up with Pfizer, Allergan PLC partnered with Sosei Group Corp.'s Heptares Therapeutics Ltd. to develop selective small-molecule muscarinic receptor agonists from Heptares' pipeline for Alzheimer's disease and related neurological diseases.
- Drug Discovery Tools
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.